Slides
Page 1
Increased profitability, strong cash flow and higher customer satisfaction Getinge Q3 2026 Mattias Perjos, CEO Agneta Palmér, CFO
Page 2
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs Getinge │ Presentation │ Q3 Report 2026 Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales 1,9 1,2 1,0 1,1 2023 2024 2025 R12 Sep 2026 -42% 60% Q3 2023 Q3 2024 Q3 2025 67% Q3 2026 Capital goods Recurring revenue 62% Q3 2023 Q3 2024 Q3 2025 70% Q3 2026 Rest of Portfolio High margin products Sales share in R12 figures. 1) Defined as products with adjusted gross margin higher than its Business Area in 2024; 2) Net debt/adj. EBITDA < 2.5; 3) ROIC at least > Weighted Average Cost of Capital Improvements should be achieved through balanced leverage2 and attractive long-term Return on Invested Capital3 Page 2 October 21, 2026
Page 3
Key takeaways Q3 2026 Getinge │ Presentation │ Q3 Report 2026 • Net sales grew by 2.1% organically and order intake increased by 2.6% organically • Healthy margins in the quarter – primarily from solid underlying improvement in the business • Strong cash flow and financial position 51 52 53 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 51.8 0 15 16 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 15.6 R12 Gross Margin (adj) % R12 EBITA Margin (adj) % 0 34,000 36,000 38,000 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 34,455 R12M Net Sales, SEK M Page 3 October 21, 2026
Page 4
Offering and Customers • All-time high in annual customer satisfaction survey • Cardiohelp II successfully launched in CE countries and Hong Kong • Launch of Torin Plan Optimizer, an AI-powered decision support solution for surgical planning • Donation of ECMO consumables to the National Specialized Children’s Hospital Okhmatdyt in Kyiv Sustainability, Quality and other • 510(k) clearance for new Edi catheter designed for premature infants weighing between 500 and 1000 grams • Scope 1 & 2 GHG emissions have improved by >20% • Share of renewable of total energy consumption at 72% Key activities and events Q3 2026 Getinge │ Presentation │ Q3 Report 2026 Edi catheter for premature infants Page 4 October 21, 2026 Torin Plan Optimizer Cardiohelp II
Page 5
Order Intake and Net Sales Bridge Q3 2025 – Q3 2026 Organic topline growth – driven by ACT and SW 126 187 8,477 Q3 2025 Acute Care Therapies -8 Life Science Surgical Workflows 8,781 Q3 2026 SEK M +3.6% +2.4% -1.4% +4.5% Organic change +2.6% 177 75 8,226 Q3 2025 Acute Care Therapies -31 Life Science Surgical Workflows 8,446 Q3 2026 SEK M +2.7% +4.5% -3.6% +0.7% +2.1% Organic change Order Intake Net Sales Getinge │ Presentation │ Q3 Report 2026 Page 5 October 21, 2026
Page 6
Adjusted Gross Profit and EBITA Bridge Q3 2025 – Q3 2026 Margins strengthened by underlying improvements and tariff refund 233 51 4,051 Q3 2025 Acute Care Therapies Life Science Surgical Workflows 4,343 Q3 2026 SEK M 8 +7.2% Adj GM, % Q3 2026 (Q3 2025) Gross Margin impact Currency Product and Geo mix Cost (incl. tariffs) Price 292 35 Q3 2026 SEK M Adj GP -26 Adj Selling -43 Adj Admin -50 Adj R&D Other OPEX D&AQ3 2025 1,079 -9 1,278 +18.4% 59.6 38.4 43.5 51.4 (36.5) (42.8) (49.2)(56.6) 13.1% 15.1% +1.7 pp Adj GP +0.1 pp Adj OPEX +0.0 pp D&A +0.3 pp FX Adjusted Gross Profit Adjusted EBITA Margin development Getinge │ Presentation │ Q3 Report 2026 Page 6 October 21, 2026
Page 7
Getinge continues to have a solid financial position Strong FCF in quarter and good safety margin on leverage FCF positively impacted by improved operating profit… 0.8 Q3 2025 1.2 Q4 2025 0.8 Q1 2026 1.0 Q2 2026 1.3 Q3 2026 Free Cash Flow, SEK B … and leverage continues to be well below 2.5x 1.6 Q3 2025 1.5 Q4 2025 1.5 Q1 2026 1.7 Q2 2026 1.6 1.5 1.5 1.7 Q3 2026 1.5 1.5 Net debt/Adj EBITDA R12 (1.1x excl. pension liabilities) Getinge │ Presentation │ Q3 Report 2026 Page 7 October 21, 2026
Page 8
Steady traction towards mid-term guidance span Closing in on the span of 16-19%* 10 11 12 13 14 15 16 17 18 19 R12 Adj. EBITA margin Q2 24 Q4 24 Q2 25 14.0 15.0 Q4 25 Q2 26 15.6 15.8 Q4 26 Q2 27 Q4 27 Q2 28 Q4 28 12.0 +3.6 pp R12 Adjusted EBITA margin Normalized, excl. tariffs (paid and refunded) Mid-term guidance span of 16-19% adj. EBITA by end of 2028 First quarter with tariffs Key levers: ∆ Significant quality cost release, gradually from H2 2026 to 2028 ∆ Mix shift to more recurring and high margin revenue ∆ Productivity gains and key product launches October 21, 2026 Getinge │ Presentation │ Q3 Report 2026 Page 8 * If excluding only the tariff refund received in Q2-Q3 2026 (SEK 381M), R12 adj. EBITA margin in Q3 was 14.5%.
Page 9
Net sales for 2026 expected to increase by 3-5% organically* Outlook 2026 * Adjusted for the phase-out of Surgical Perfusion, which is expected to have net sales in 2026 declining from about 250 MSEK to 50 MSEK Getinge │ Presentation │ Q3 Report 2026 Page 9 October 21, 2026
Page 10
Summary Getinge │ Presentation │ Q3 Report 2026 Page 10 October 21, 2026
Page 11
Key takeaways Summary Q3 2026 • Net sales grew by 2.1% organically and order intake increased by 2.6% organically • Healthy margins in the quarter – primarily impacted by solid underlying improvement • Strong cash flow and financial position • Outlook for 2026: organic net sales growth of 3-5%, adjusted for the phase-out of Surgical Perfusion Getinge │ Presentation │ Q3 Report 2026 Page 11 October 21, 2026
Page 12
Q&A Getinge │ Presentation │ Q3 Report 2026 Page 12 October 21, 2026
Page 13
Appendix – Equity story Getinge │ Presentation │ Q3 Report 2026 Page 13 October 21, 2026
Page 14
World-leading Medtech at an inflection point Quality cost release beginning H2 2026, the operational inflection is visible WHO WE ARE INVESTMENT CASE #1-2 positions in core categories ➢ SEK ~35 B revenue, 67% recurring ➢ SEK 200 B addressable market growing 4-6% per year ➢ Sole or dual-source supplier in several critical customer categories ➢ Quality resolution on track – 42% reduction in field actions KPI1 #1-2 positions 30,000 customers 135 countries 2023 2024 2025 +2-5pp Growth, Mix & Productivity 16-19 2028 12.2 14.0 14.0 Visible margin recovery Underlying improvement masked in 2025 by SEK ~1 B tariff & FX headwind2 Adj. EBITA margin (%) Significant quality cost release ~Gradually from H2 2026 to 2028 SHAREHOLDER RETURN Prioritised dividend and healthy leverage Mix shift to recurring From 61% to 67% since 2023 Productivity gains & innovation Share of high margin products at 70% >12% Adj. EPS CAGR Financial target 2024-20283 30-50% of net profit Seven consecutive years of dividend growth Dividend policy 1.5x4 Significant headroom vs. 2.5x threshold Net debt to adj. EBITDA in Q2 2026 Near-term Ongoing Ongoing 1 Reduction in Field Actions per Bn SEK net sales since 2023; 2 Majority of paid tariffs were refunded in Q2 2026 (36 MUSD); 3 Base year 2023; 4 1.1x excluding pensions Page 14 Getinge │ Presentation │ Q3 Report 2026 October 21, 2026
Page 15
Thank you Getinge │ Presentation │ Q3 Report 2026 Page 15 October 21, 2026
Page 16
This document contains forward-looking information based on the current expectations of Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates. Forward-looking information Getinge │ Presentation │ Q3 Report 2026 Page 16 October 21, 2026